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Questions have been raised over the acceptability of conducting human challenge studies
in low and middle income countries (LMICs). Most of these concerns are based on theoreti-
cal considerations and there exists little data on the attitudes of stakeholders in these coun-
tries. This study examines the view of researchers and REC members in Thailand regarding
the design and conduct of challenge studies in the country. A questionnaire was developed
based on ethical frameworks for human challenge studies. The target respondents included
those who had experience with health-related research at universities, non-university hospi-
tals, and research institutes. A total of 240 respondents completed the on-line survey. In
general, the respondents felt that the ethical issues raised by human challenge studies in
LMICS do not differ significantly from those in high income countries, including: scientific
rationale, safety, appropriate risks, and robust informed consent process. In contrast, issues
that have been described as important for human challenge studies in LMICs were rated as
having lower importance, including: a publicly available rationale, national priority, and com-
munity engagement. Responses did not vary significantly between researchers in different
fields, nor between researchers and REC members. These findings provide an important
perspective for assessing existing frameworks for human challenges studies in LMICs.
Introduction
Human challenge studies involve the intentional infection of study participants with disease-
causing pathogens as a means to assess potential vaccines or drug candidates, or to understand
how humans are protected from or acquire the infection [1–5]. Many commentators agree
that such studies may be approved when they satisfy a number of requirements, including: a
highly controlled environment, robust informed consent, and effective treatment for the







Citation: Kaewkungwal J, Adams P, Sattabongkot
J, Lie RK, Wendler D (2019) Conducting human
challenge studies in LMICs: A survey of
researchers and ethics committee members in
Thailand. PLoS ONE 14(10): e0223619. https://doi.
org/10.1371/journal.pone.0223619
Editor: Rieke van der Graaf, University Medical
Center Utrecht, NETHERLANDS
Received: June 19, 2019
Accepted: September 24, 2019
Published: October 10, 2019
Copyright: This is an open access article, free of all
copyright, and may be freely reproduced,
distributed, transmitted, modified, built upon, or
otherwise used by anyone for any lawful purpose.
The work is made available under the Creative
Commons CC0 public domain dedication.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: The authors received no specific funding
for this work.
Competing interests: I have read the journal’s
policy and the authors of this manuscript have the
following competing interests: David Wendler
works for the US NIH Clinical Center. However, the
views expressed are the authors’ own. They do not
infection [6]. Permitting human challenge studies under these conditions is consistent with
the more general view that it can be permissible to expose research participants to greater than
minimal risk when the study is valuable, the risks are not excessive, participants give informed
consent, and participants are compensated for any research harms [3,4,6].
To date, most human challenge studies have been conducted in high income countries.
With technological advancement, well-established laboratory facilities and increasing capacity,
some have proposed that challenge studies might also be conducted in low and middle income
countries (LMICs) [7–13]. Others express concern over whether these studies would be appro-
priate. In particular, questions have been raised over the safety of participants and the avail-
ability of suitable care for (infected) participants in LMICs. Further concerns expressed are
whether the public in LMICs would accept human challenge studies and the possibility that
participants might be unduly induced to participate by offers of (excessive) payment [14].
These concerns over conducting human challenge studies in LMICs are based on theoreti-
cal considerations and there exists little data on the attitudes of stakeholders in these countries.
The present study was designed to address this gap in the literature. Thailand, as one of the
LMICs, has conducted a few human challenge studies including, for example, trials on con-
trolled human malaria infection, oral inoculation with Vibrio cholerae, and Shigella sonnei vac-
cine [7–9]. Specifically, this study examines the view of researchers and REC members in
Thailand. Do they believe that conducting human challenge studies in Thailand would be
appropriate? What do they regard as the most important concerns raised by these studies?
Materials and methods
Target study respondents
The target respondents were REC members and researchers who had experience with health-
related research at universities, non-university hospitals, and research institutes. We attempted
to identify respondents from a range of fields, including biomedicine, pharmacology, clinical
practice, epidemiology and public health, and behavioral-social science,
Data collection
Paper-based and online versions of the survey were developed. The on-line survey was distrib-
uted via e-mails that contained a link to the questionnaire. The paper-based and online ver-
sions of the survey were distributed to 218 participants from 38 academic and health-science
institutes across Thailand who were participating in a 2018 workshop on human research
studies organized by the Office of Research Services of the Faculty of Tropical Medicine
(FTM), Mahidol University. The online version was subsequently sent to the heads of the
research offices at 18 university hospitals, 84 non-university hospitals, and 22 research insti-
tutes, as well as alumni and researchers who had previously submitted proposals to and/or par-
ticipated in workshops conducted by FTM. In total, 2,656 emails were sent from FTM. In
addition, recipients of the on-line survey were asked to forward it to colleagues in their field.
Recipients were informed that completing the survey was voluntary. The survey was anony-
mous, and not linked to the submitting source. Completed surveys were uploaded automati-
cally to a database.
Questionnaire development
Step 1. Identifying issues raised by challenge studies. A review of international and local
ethics guidelines, as well as discussions in scientific journals, was used to identify the important
ethical issues related to designing and conducting human challenge studies. This search
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represent the position or policy of the US NIH or
federal government.
identified a number of frameworks and best practices [3–6]. One framework was based on
interviews with experts on challenge studies. This framework focuses on: ensuring volunteer
safety; assessing the potential for transmission to third parties; considering the potential public
health impact; ensuring there are no alternative means to gather the same information; and
collecting reliable and relevant data [15].
A second framework was developed by a committee consisting of US federal employees,
researchers, and ethicists organized by the National Institute of Allergy and Infectious Diseases
(NIAID) and the Walter Reed Army Institute of Research (WRAIR). This framework discusses
8 issues relevant to challenge trials involving Zika virus: (1) minimizing risks and ensuring the
remaining risks are justified by the potential social value of the study; (2) protecting vulnerable
populations; (3) ensuring informed consent process; (4) offering adequate but not undue levels
of compensation; (5) guaranteeing the right to withdraw;(6) obtaining independent expert
review; (7) providing compensation for research injury; and (8) obtaining community engage-
ment [15].
A third framework describes 5 common criteria for any trial involving human subjects and
4 criteria specific to human challenge studies [6]. The five common criteria are: (1) potential to
collect important scientific knowledge; (2) absence of satisfactory alternative methods; (3)
robust informed consent from competent adult volunteers; (4) acceptable risk-benefit ratio;
and (5) equitable selection of study participants. The four criteria specific to challenge trials
are: (6) independent expert/systematic review; (7) publicly available rationale and protection
of public confidence; (8) protection of the public from the infection; and (9) compensation for
any research harms.
A final framework for potential human challenge studies in Malawi addressed 7 major
issues: (1) importance of informed consent, (2) value of the study for Malawi; (3) capacity
development in the country; (4) strong scientific basis for the study, with no feasible alterna-
tives, (5) appropriate design based on the published literature; (6) governance (e.g., DSMB,
sponsor); and (7) safety of the pathogen [3].
The questionnaire used for the present study was based on these frameworks as well as the
expanded framework for the ethical evaluation of human challenge studies developed by
Emerson and Cullen [16]. Based on this work, we identified the following sixteen items as
potential concerns raised by human challenge studies in general: scientific rationale, absence
of alternatives, technical considerations, independent review, informed consent, risks and
harms, balance of risks and benefits, safety, selection of participants, compensation for harms,
publicly available rationale, protection of the public, knowledge and data sharing, community
engagement, governance, and national priority. We further identified the following 9 as poten-
tial concerns for conducting human challenge studies in LMICs: Quality assurance / quality
control; Good manufacturing practices; Appropriate compensation; Community perception
and engagement; Sponsorship and intellectual property rights; Readiness of infrastructure;
National priority; Community acceptance; Vulnerable subjects (S1 File)
Respondents were asked to rate the importance of each issue on a Likert scale from 1–5,
with 1 indicating least important and 5 indicating most important.
Step 2. Determining the validity of the questionnaire items. The questionnaire was
developed in both English and Thai, as the respondents included Thai and non-Thai research-
ers in different organizations. Three REC members of the Faculty of Tropical Medicine
reviewed a draft of the questionnaire for face validity. The dual-language questionnaire was
cross-validated by a native English speaker.
Step 3. Test of the online questionnaire. No formal pilot study of the final questionnaire
was performed. Instead, the paper-based and on-line versions were distributed to participants
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in the workshop who were asked to provide feedback. The workshop participants did not iden-
tify any significant issues, so the questionnaire was considered acceptable.
Data analysis
We assumed that responses regarding the importance of the listed items would skew toward
the upper range of the scale. Thus, we collapsed the 5-point scale into 3 categories: 5 = very
important, 4 = important, and 1–3 = less important. We then calculated a frequency and per-
centage by respondent characteristics: clinical and non-clinical researchers, and researchers
and REC members. Rating level comparisons were evaluated using chi-square tests, with a p-
value of<0.05 considered statistically significant.
Ethical clearance
This project was approved by The Ethics Committee of the Faculty of Tropical Medicine,
Mahidol University, Thailand, with Certificate of Approval Number MUTM-EXMPT 2018–
003. The Ethics Committee certified that the study protocol was in compliance with the Decla-
ration of Helsinki, ICH Guidelines for Good clinical Practice, and other international guide-
lines for human research protection. We confirm that informed consent was obtained
voluntarily from all participants. No identifiers could link to the identities of the questionnaire
respondents. They could also decide not to answer any question in the questionnaire, without
any negative impact.
Results
Characteristics of the survey respondents
A total of 240 respondents completed the survey (S2 File). Based on the 2,656 surveys known
to have been distributed, this suggests an overall response rate of 9% (240/2,656). As shown in
Table 1, the ratio of male to female respondents was 30:70. Half of the respondents worked
Table 1. Characteristics of study respondents (N = 240).
Characteristics of respondents n %
Sex
• Male 71 29.6
• Female 169 70.4
Main research field:
• Clinical study 123 51.3
• Biomedical/laboratory study 60 25.0
• Public health/Policy research 17 7.1
• Social science/behavioral research 28 11.7
• Other 12 5.0
Years working in research field:
• 1–3 48 20.4
• 4–6 32 13.6
• 7–10 33 14.0
• 1–15 36 15.3
• > 15 86 36.6
Experience on an ethics committee
• No 164 68.3
• Yes 76 31.7
https://doi.org/10.1371/journal.pone.0223619.t001
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mainly in clinical studies, while the other half worked in basic and applied sciences. Years of
experience ranged from 1–3 years to> 15 years. About 30% of respondents reported current
or previous experience as the member of an ethics committee.
Considerations regarding designing and conducting challenge studies
As expected, most of the items were rated as very important (5) or important (4). As shown in
Table 2, >80% of respondents rated as very important: safety, informed consent, scientific
rationale, risks and harms. The issues rated by>70% of respondents as very important were:
governance, balance of risk-benefit, and protection of public. About 60–68% of respondents
rated as very important: selection of study participants, compensation for harm and publicly
available rationale. The issues that > 50–58% of respondents rated as very important included:
knowledge and data sharing, technical considerations, independent review, absence of alterna-
tive, national priority, and community engagement.
The ratings of clinical and non-clinical researchers were similar to the overall ratings and
we did not identify any statistically significant differences in their responses (Table 3). Respon-
dents with present or previous experience as REC members were more likely to rate items as
very important (5) compared to respondents who lacked experience as REC members
(Table 4). These differences led to statistically significant differences between the two groups
regarding the importance of: balance of risk-benefit (rated as very important by 80% of REC
members vs. 74% of researchers, p-value = 0.05) and selection of study participants (rated as
very important by 74% of REC members vs. 66% of researchers, p-value < 0.01).
Concerns about conducting challenge studies in Thailand
As shown in Table 5, about 40% of respondents rated as very important the quality assurance /
quality control procedures of human challenge studies conducted in Thailand. About 30%
rated as very important and 40% rated as important the following issues: appropriate compen-
sation, community perception and engagement, and intellectual propriety rights of the
Table 2. Ratings of important issues in designing and conducting challenge studies (N = 240).
Important Issues in Designing and Conducting Challenge Studies Total (N = 240)
Very Important (5) Important (4) Less Important (1–3)
n (%) n (%) n (%)
Safety 215 (89.6) 23 (9.6) 2 (0.8)
Informed consent 208 (86.7) 30 (12.5) 2 (0.8)
Scientific rationale 201 (83.8) 33 (13.7) 6 (2.5)
Risks and harms 198 (82.5) 37 (15.4) 5 (2.1)
Governance 187 (77.9) 46 (19.2) 7 (2.9)
Balance of risks and benefits 182 (75.8) 54 (22.5) 4 (1.7)
Protection of public 176 (73.3) 59 (24.6) 5 (2.1)
Selection of study participants 165 (68.7) 68 (28.3) 7 (2.9)
Compensation for harm 162 (67.5) 71 (29.6) 7 (2.9)
Publicly available rationale 150 (62.5) 85 (35.4) 5 (2.1)
Knowledge and data sharing 140 (58.3) 88 (36.7) 12 (5.0)
Technical considerations 139 (57.9) 88 (36.7) 13 (5.4)
Independent review 130 (54.2) 92 (38.3) 18 (7.5)
Absence of alternatives 128 (53.3) 85 (35.4) 27 (11.3)
National priority 122 (50.8) 95 (39.6) 23 (9.6)
Community engagement 121 (50.4) 93 (38.8) 26 (10.8)
https://doi.org/10.1371/journal.pone.0223619.t002
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finished product. Fewer respondents rated as very important readiness of infrastructure,
national priority, community acceptance, and vulnerabilities pertaining to the informed con-
sent process.
The level of concern was compared by types of respondents (S1 Table). More clinical
researchers (34.2%) compared to non-clinical researchers (25.6%) rated as very important
sponsorship and intellectual property rights (p-value = 0.01). More researchers with REC
Table 3. Comparisons of ratings about challenge studies by clinical and non-clinical researchers.
Issues in Designing and Conducting Challenge Studies Clinical (N = 123) Non-Clinical (N = 117) p-value
Very Important Important Less Important Very Important Important Less Important
n (%) n (%) n (%) n (%) n (%) n (%)
Safety 113 (91.9) 8 (6.5) 2 (1.6) 102 (87.2) 15 (12.8) 0 (0.0) 0.10
Informed consent 108 (87.8) 13 (10.6) 2 (1.6) 100 (85.5) 17 (14.5) 0 (0.0) 0.26
Scientific rationale 101 (82.1) 18 (14.6) 4(3.3) 100 (85.5) 15 (12.8) 2 (1.7) 0.67
Risks and harms 103 (83.7) 17 (13.8) 3 (2.4) 95 (81.2) 20 (17.1) 2 (1.7) 0.74
Governance 98 (79.7) 23 (18.7) 2 (1.6) 89 (76.0) 23 (19.7) 5 (4.3) 0.46
Balance of risk-benefit 95 (77.2) 26 (21.1) 2 (1.6) 87 (74.4) 28 (23.9) 2 (1.7) 0.87
Protection of public 99 (73.1) 29 (23.6) 4 (3.3) 86 (73.5) 30 (25.6) 1 (0.9) 0.42
Selection of study participants 81 (65.9) 40 (32.5) 2 (1.6) 84 (71.8) 28 (23.9) 5 (4.3) 0.19
Compensation for harm 82 (66.7) 37 (30.0) 4 (3.3) 80 (68.4) 34 (29.0) 3 (2.6) 0.93
Publicly available rationale 78 (63.4) 42 (34.2) 3 (2.4) 72 (61.5) 43 (36.8) 2 (1.7) 0.86
Knowledge and data sharing 70 (56.9) 47 (38.2) 6 (4.9) 70 (59.8) 41 (35.0) 6 (5.1) 0.88
Technical considerations 70 (56.9) 48 (39.0) 5 (4.1) 69 (59.0) 40 (34.2) 8 (6.8) 0.53
Independent review 69 (56.1) 43 (35.0) 11 (8.9) 61 (52.1) 49 (41.9) 7 (6.0) 0.44
Absence of alternative 71 (51.7) 38 (30.9) 14 (11.4) 57 (48.7) 47 (40.2) 13 (11.1) 0.31
National priority 65 (52.8) 50 (40.7) 8 (6.5) 57 (48.7) 45 (38.5) 15 912.8) 0.25
Community engagement 56 (45.5) 53 (43.1) 14 (11.4) 65 (55.5) 40 (34.2) 12 (10.3) 0.29
https://doi.org/10.1371/journal.pone.0223619.t003
Table 4. Comparisons of ratings about challenge studies by researchers and REC members.
Issues in Designing and Conducting Challenge Studies REC members (N = 76) Researchers (N = 164) p-value
Very Important Important Less Important Very Important Important Less Important
n (%) n (%) n (%) n (%) n (%) n (%)
Safety 69 (90.8) 6 (7.9) 1 (1.3) 146 (89.0) 17 (10.4) 1 (0.6) 0.72
Informed consent 69 (90.8) 7 (9.2) 0 (0.) 139 (84.8) 23 (14.0) 2 (1.2) 0.35
Scientific rationale 63 (82.9) 11 (14.5) 2 (2.6) 138 (84.2) 22 (13.4) 4 (2.4) 0.97
Risks and harms 62 (81.6) 11 (14.5) 1 (3.9) 136 (82.9) 26 (15.9) 2 (1.2) 0.38
Governance 62 (81.6) 10 (13.2) 4 (5.2) 125 (76.2) 36 (22.0) 3 (1.8) 0.11
Balance of risk-benefit 61 (80.3) 12 (15.8) 3 (3.9) 121 (73.8) 42 (25.6) 1 (0.6) 0.05
Protection of public 54 (71.1) 20 (26.3) 2 (2.6) 122 (74.4) 39 (23.8) 3 (1.8) 0.83
Selection of study participants 56 (73.7) 14 (18.4) 6 (7.9) 109 (66.5) 54 (32.9) 1 (0.6) <0.01
Compensation for harm 54 (71.1) 19 (25.0) 3 (3.9) 108 (65.9) 52 (31.7) 4 (2.4) 0.50
Publicly available rationale 46 (60.5) 28 (36.8) 2 (2.6) 104 (63.4) 57 (34.8) 3 (1.8) 0.86
Knowledge and data sharing 44 (57.9) 25 (32.9) 7 (9.2) 96 (58.5) 63 (38.4) 5 (3.1) 0.11
Technical considerations 44 (57.9) 30 (39.5) 2 (2.6) 95 (57.9) 58 (35.4) 11 (6.7) 0.40
Independent review 45 (59.2) 23 (39.3) 8 (10.5) 85 (51.8) 69 (42.1) 10 (6.1) 0.15
Absence of alternative 39 (51.3) 32 (42.1) 5 (6.6) 89 (54.3) 53 (32.3) 22 (13.4) 0.16
National priority 40 (52.6) 28 (36.9) 8 (10.5) 82 (50.0) 67 (40.9) 15 (9.1) 0.83
Community engagement 40 (52.6) 30 (39.5) 6 (7.9) 81 (49.4) 63 (38.4) 20 (12.2) 0.60
https://doi.org/10.1371/journal.pone.0223619.t004
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experience (46.1%) than researchers without REC experience (29.9%) rated as very important
appropriate compensation for risk-taking (p-value = 0.04). More researchers with REC experi-
ence (38.2%) than researchers without REC experience (22.6%) rated as very important
national priority and opportunity costs for products if the study is successful (p-value = 0.03).
Discussion
Recently a number of reports and publications have called for greater involvement of LMICs
in the conduct of human challenge studies. At the same time, worries have been raised about
the ethics of these studies. Ethics frameworks for human challenge studies conducted in the
US and Europe focus on ensuring the study is valuable, the risks are not excessive, and subjects
give valid consent. A number of commentators have argued that these issues, although impor-
tant, are not sufficient to ensure the ethical conduct of human challenge studies in LMICs.
They argue that human challenge studies in LMICs need to satisfy a number of additional con-
ditions. These include: community engagement, publicly available rationale, appropriate gov-
ernance, appropriate data sharing, and compensation for research harms.
To our knowledge, this is the first study that provides empirical data regarding the attitudes
among key stakeholders to human challenge studies in LMICs. As we anticipated, most
respondents rated each of the 25 items as very important or important. Our discussion thus
focuses on ratings of 5 (very important) as indicating the priorities of the respondents. These
findings are important in several respects.
First, our study confirms the importance of the concerns that have been cited for human
challenge studies in high-income countries: scientific rationale, safety, appropriate risks, and
robust informed consent process. Specifically, more than 80% of respondents rated these con-
siderations as very important. In contrast, the additional issues that have been described as
important for human challenge studies in LMICs were rated as having lower importance. In
particular, a publicly available rationale, national priority, and community engagement were
rated as being less important. These results suggest that, in the view of important stakeholders
in Thailand, the ethical issues raised by human challenge studies in LMICS do not differ signif-
icantly from the ethical issues raised by human challenge studies in high income countries
[2,3,6,17,18]. Human challenge studies with promising results from high-income settings
might require replications in LMICs due to the differences in host-pathogen relationships
and/or disease epidemiology. The World Health Organization has noted that human challenge
Table 5. Opinions regarding conducing challenge studies in Thailand.





n (%) n (%) n (%)
Quality assurance / quality control procedures in the agent used in challenge study following Good Manufacturing
Practice principles
104 (43.3) 82 (34.2) 54 (22.5)
Appropriate compensation for risk-taking 84 (35.0) 98 (40.8) 58 (24.2)
Community perception and engagement with respect to the understanding of infection risk, disease severity, treatment
availability
83 (34.6) 98 (40.8) 59 (24.6)
Sponsorship and intellectual propriety rights of the finished product 72 (30.0) 97 (40.4) 71 (29.6)
Readiness of infrastructure and clinical facilities for challenge study 67 (27.9) 114 (47.5) 59 (24.6)
National priority and opportunity costs for products if the study is proved a success 66 (27.5) 121 (50.4) 53 (22.1)
Community acceptance (cultural family/group consenting) 57 (23.7) 119 (49.6) 64 (26.7)
Inherent vulnerabilities about informed consent in the local context (languages, assessment understanding, participant
criteria suitability)
54 (22.5) 104 (43.3) 82 (34.2)
https://doi.org/10.1371/journal.pone.0223619.t005
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trials have been, and can be, successfully conducted in low- and middle-income settings by
applying the same standards as in more developed countries [2]. While the conduct of chal-
lenge trials in LMICs often involves higher levels of vulnerability, the study design should
employ “equivalent international” standards, including key ethical issues of acceptable levels of
risk and adequately informed consent [3], which were major concerns of the participants in
this study.
We found no statistically significant differences in these responses between respondents
working primarily in clinical research vs. those working in nonclinical research. Similarly, we
found that researchers and REC members had similar views, with the exception of risk-benefit
balance and selection of study participants; i.e., more REC members than researchers rated
very important for these two issues. A previous study among similar groups of researchers and
ethics committee members in Thailand explored their opinions regarding ethical consider-
ations of the research proposal and the informed-consent process in research in general, not
particularly to challenge studies [19]. The results of that study identified more discrepancies of
opinions between the two groups, including risk/benefit, vulnerability, confidentiality/privacy,
communication of risks, decision-making authority for consent, process for approaching
study participants, and the availability of a contact for study deviations/violations [19]. The
present study suggests that the perceptions and concerns about challenge studies are general
among researchers, and do not differ that much by research field or with experience as an REC
member.
The issues that our respondents rated as most important for human challenge studies in
Thailand also provide perspective on recent proposals in the literature. Worry about quality
assurance is on top of the list, whereas worries about “inherent vulnerabilities about informed
consent in the local context” are lowest on the list. This suggests that concerns regarding the
vulnerability of participants in LMICs are not shared by important stakeholders in Thailand.
As recommended in the ethics frameworks for challenge studies, the study participants are
required to be closely monitored for safety as well as for prevention of infection to others and
the environment1. This study revealed the topmost important consideration about challenge
studies in the view of researchers in Thailand is safety; about 90% of respondents in this study
rated safety as very important. This finding reflects common concern among researchers in
LMICs as well as those in high income countries regarding safety as the major ethical principle
in designing and conducting challenge studies or other types of clinical trials.
Similarly, in contrast to the existing literature [1,6], respondents did not regard a potential
lack of community acceptance as an important obstacle to human challenge studies in Thai-
land. This finding contrasts with a report of lessons learnt from a malaria infection study in
Kenya. In that study, the researchers emphasized the importance of public engagement in pro-
moting community perceptions of risk, disease severity, treatment availability and the baseline
knowledge about the vaccines used in designing the study [12,17].
Only about one-fourth of researchers in our sample had significant concern for the readi-
ness of infrastructure and clinical facilities for challenge studies in Thailand. This might be due
to the fact there are several well-equipped laboratories and facilities and a well-established
health care system in the country. These issues may be of greater concern in other LMICs
[1,3,16].
Commentators have argued that human challenge studies should be conducted in LMICs
only when they are a priority for the community [3,20]. WHO emphasizes that challenge stud-
ies should be judged by the degree of alignment with the national research agenda and needs
for the study outcomes [3,4]. However, only about half of the respondents in Thailand rated
national priority as very important.
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Approximately 80% of the researchers rated as very important governance of human chal-
lenge studies in Thailand. This finding suggests, consistent with existing frameworks, that
researchers in Thailand regard good governance as very important, including having data
monitoring and safety boards and other relevant committees, standard operating procedures
for conducting the study, qualified investigators, and a high level of quality control [3,15]. As
part of good governance, several frameworks endorsed a separate group to review and approve
the proposal, in addition to the standard ethics committee [2,6,21]. In this study, only about
54% of researchers rated independent review as very important.
Limitations of the study
Our study had a number of limitations. First, the overall response rate (9%) was very low
based on the 240 completed returned online questionnaires against the 2,656 email invitations
that were sent out. Second, we performed the online survey distributing to two batches of the
potential study population: (1) the 218 participants from 38 institutes who were participating
in our workshop on human research studies, and (2) the heads of the research offices at 18 uni-
versity hospitals, 84 non-university hospitals, and 22 research institutes. It should also be
noted that the workshop did have a session on CHIM and there was a post-conference forum
focused on CHIM, but only very few participants who were also ethics committee members
from the main workshop attended this forum. As it was an anonymous survey, we did not
know the sources/locations of the respondents; it might be that most of the respondents
among the 240 returned questionnaire were from the 218 participants who attended the work-
shop. This may have biased the results. Third, most of the surveys were completed on-line and
the views of individuals who lacked access to the internet may differ. This concern may be
minimal for the present survey, given that the target respondents were researchers who were
working in academic institutes and who generally had access to the internet as an integral part
of their work. Fourth, we planned the study based on the survey on issues around the themes
of the workshop we arranged. We believed that we have reviewed intensively and identified
most of the important issues of human challenge models and concepts found in the literature.
In our questionnaire, we defined the terminology of each item based on definitions found in
the literature and attempted to rephrase it into simple language which was edited by a native
English-speaking reviewer. We attempted to assess the perspectives on our key issues of inter-
est among our target population. Thus the questionnaire might have been too specific and
introduced information bias. Our study is limited to the views of professional stakeholders in
Thailand. The view of the general public in Thailand and the views of professional stakeholders
in other LMICs may differ. Finally, our study focused on the perspectives of stakeholders,
including researchers and ethics committee members, but not members of the general com-
munity. In fact, there will be a CHIM study, funded by the Welcome Trust, on malaria vaccine
in late 2019 and the researchers in that trial have been working on community engagement.
The results of that study on community attitudes will complement the present study, which
has presented only the viewpoints of researchers and ethics committee members.
Conclusions
It is widely agreed that human challenge studies should satisfy a number of important ethical
considerations. In addition, some commentators have argued that human challenge studies
conducted in LMICs raise additional important ethical concerns. These include the impor-
tance of obtaining community input and ensuring the studies reflect national priorities. How-
ever, the respondents in the present survey, researchers and REC members in Thailand, do not
appear to share these concerns. Instead, we found wide agreement on the ranking of the
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importance of ethical issues in our sample, consisting of both clinicians and non-clinicians,
researchers and REC members. The fact that we have found a consistent pattern across a diver-
sity of backgrounds, strengthens the conclusions.
This study reveals perceptions and concerns about challenge studies among researchers in
Thailand. The researchers in clinical study and non-clinical research fields were not different
in their opinions regarding the core considerations in designing and conducting the challenge
studies. The researchers and the REC members also hold similar opinions regarding those
core considerations, except a few issues. In general, the researchers in Thailand regard as most
important: safety, informed consent process, scientific rationale, risks and harms, governance
and balance of risk-benefit, respectively. If challenge studies are conducted in Thailand, major
concerns that should be taken into consideration were: quality assurance procedures, appro-
priate compensations, community perceptions, sponsorship and intellectual propriety rights,
and cost of the finished product.
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